SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer

• Published in: Clinical cancer research
• Main Authors: Chae, Young Kwang, Othus, Megan, Patel, Sandip Pravin, Wilkinson, Kelly J, Whitman-Purves, Emily M, Lea, Jayanthi, Schallenkamp, John M, Adra, Nabil, Appleman, Leonard J, Alden, Mitchell, Thomes Pepin, Jessica, Ellerton, John A, Poklepovic, Andrew, Walter, Adam, Rampurwala, Murtuza M, Robinson, William R, Kim, Hye Sung, Chung, Liam Il-Young, McLeod, Christine M, Lopez, Gabby, Chen, Helen X, Sharon, Elad, Streicher, Howard, Ryan, Christopher W, Blanke, Charles D, Kurzrock, Razelle
• Format: Journal Article
• Language: English
• Published: United States 17.10.2024

The role of dual checkpoint inhibition in advanced rare/ultra-rare non-epithelial ovarian cancers (NEOCs) is yet to be explored. DART is a prospective, multicenter (1,016 US sites), multi-cohort, single-arm phase II trial conducted through the Early Therapeutics and Rare Cancer SWOG/NCI Committee, a...